Ladenburg Thalmann Upgrades Repros Therapeutics (RPRX) to Buy
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Ladenburg Thalmann upgraded Repros Therapeutics (NASDAQ: RPRX) from Neutral to Buy with a price target of $5.50.
Shares of Repros Therapeutics closed at $1.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Upgrades CVR Refining (CVRR) to Outperform; Most Exposed to RINs
- JPMorgan Upgrades PACCAR (PCAR) to Neutral
- BofA/Merrill Lynch Upgrades Scotts Miracle-Gro (SMG) to Buy
Create E-mail Alert Related CategoriesHot Upgrades, Upgrades
Related EntitiesLadenburg Thalmann Financial Services
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!